Vera Therapeutics is trading 9.45% up after hours at $32.60, following third-quarter results and raised 2026 revenue guidance. - The price compares with the $29.79 regular-session close on November 6. - TRUTAKNA generated $10.3 million in initial product revenue, with about 700 Patient Start Forms since launch. - Management raised 2026 revenue guidance to $22 million–$25 million from $12 million–$15 million, citing launch momentum. No after-hours volume data was provided.